Marrone Bio Innovations logo

Marrone Bio Innovations (NASDAQ:MBII – Get Rating) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Friday.

Several other analysts also recently commented on the stock. Zacks Investment Research upgraded shares of Marrone Bio Innovations from a “sell” rating to a “hold” rating in a report on Friday, March 18th. Canaccord Genuity Group downgraded shares of Marrone Bio Innovations from a “buy” rating to a “hold” rating and dropped their target price for the stock from $2.00 to $1.30 in a report on Friday, March 18th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $2.01.

Shares of NASDAQ:MBII remained flat at $$0.97 during mid-day trading on Friday. 279,663 shares of the company were exchanged, compared to its average volume of 889,192. The company has a debt-to-equity ratio of 0.26, a quick ratio of 0.75 and a current ratio of 0.94. The company has a market cap of $176.88 million, a price-to-earnings ratio of -8.09 and a beta of 0.36. The stock has a fifty day moving average of $0.97 and a 200 day moving average of $0.81. Marrone Bio Innovations has a 1-year low of $0.55 and a 1-year high of $1.95.

(Ad)

Charlie Shrem is like the “Godfather of Cryptocurrencies”. He discovered Bitcoin when it was trading for $5. Ethereum at $109. Binance at just $6. Cardano for 5 CENTS.

Today, he’s sharing the details of a $0.21 CENT crypto with Top 5 Potential… as well as his BIG prediction for May 20th.

Marrone Bio Innovations (NASDAQ:MBII – Get Rating) last announced its earnings results on Wednesday, May 11th. The basic materials company reported ($0.04) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.02). Marrone Bio Innovations had a negative return on equity of 50.77% and a negative net margin of 37.35%. During the same quarter last year, the company earned ($0.02) EPS. On average, equities research analysts expect that Marrone Bio Innovations will post -0.05 EPS for the current fiscal year.

In other Marrone Bio Innovations news, Director Pamela G. Marrone sold 22,728 shares of the business’s stock in a transaction that occurred on Thursday, March 24th. The stock was sold at an average price of $1.11, for a total transaction of $25,228.08. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 5.00% of the stock is owned by company insiders.

A number of large investors have recently modified their holdings of the stock. SG Americas Securities LLC bought a new position in Marrone Bio Innovations during the third quarter worth about $31,000. Philadelphia Trust Co. acquired a new stake in shares of Marrone Bio Innovations in the fourth quarter valued at approximately $39,000. Allspring Global Investments Holdings LLC bought a new position in shares of Marrone Bio Innovations during the 1st quarter worth approximately $43,000. Wells Fargo & Company MN increased its holdings in shares of Marrone Bio Innovations by 676.8% during the 4th quarter. Wells Fargo & Company MN now owns 60,982 shares of the basic materials company’s stock worth $44,000 after acquiring an additional 53,132 shares during the last quarter. Finally, Clear Harbor Asset Management LLC increased its holdings in shares of Marrone Bio Innovations by 41.1% during the 4th quarter. Clear Harbor Asset Management LLC now owns 75,677 shares of the basic materials company’s stock worth $55,000 after acquiring an additional 22,027 shares during the last quarter. Institutional investors and hedge funds own 68.42% of the company’s stock.

About Marrone Bio Innovations (Get Rating)

Marrone Bio Innovations, Inc discovers, develops, and sells biological products for crop protection, crop health, and crop nutrition. Its products include Emergen, Foramin, Foramin ST, Optima, Takla, Pacesetter, Ympact, UBP, and UBP ST for increasing crop health, yield, and quality; Grandevo, a bioinsecticide that controls sucking and chewing insects through feeding; Haven, a plant health product to reduce sun stress and dehydration; Jet-Ag and Jet-Oxide peroxyacetic acid sanitizers that prevent, suppress, eliminate, and control algae, fungi, and bacterial diseases in agriculture and horticultural industries; and Majestene, a bionematicide to control soil-dwelling nematodes and certain soil borne insects.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in Marrone Bio Innovations right now?

Before you consider Marrone Bio Innovations, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Marrone Bio Innovations wasn’t on the list.

While Marrone Bio Innovations currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 

#StockNewscom #Lowers #Marrone #Bio #Innovations #NASDAQMBII #Sell

Leave a Reply

Your email address will not be published.